Cytolytic effects of alloantiserum in patients with lymphoproliferative disorders.
D000293:Adolescent; D000368:Aged; D001792:Blood Platelets / Q000187:drug effects; D003490:Cyanosis / Q000139:chemically induced; D004417:Dyspnea / Q000139:chemically induced; D005260:Female; D005334:Fever / Q000139:chemically induced; D006454:Hemoglobins / Q000032:analysis; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D007106:Immune Sera / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D007116:Immunization, Passive; D007275:Injections, Intravenous; D007945:Leukemia, Lymphoid / Q000628:therapy*; D007958:Leukocyte Count; D008198:Lymph Nodes / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects*; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D006454:Hemoglobins; D007106:Immune Sera